Aprepitant Reduces Nicotine Neurotoxicity in Lab Study
Researchers found that the drug aprepitant mitigated nicotine-induced brain inflammation and behavioral changes in male Wistar rats.
Updated on Oct. 30, 2026 in Alzheimer’s
A study using 48 male Wistar rats found that administering aprepitant successfully decreased neuroinflammation and behavioral deficits caused by nicotine. The results suggest the treatment may offer protective effects against neurotoxicity in the hippocampus.
Why it matters
The findings explore potential pharmacological interventions for nicotine-induced brain damage, highlighting how neuroprotective drugs could address damage to hippocampal regions. By examining specific molecular markers, researchers aim to better understand the mechanisms of cognitive and mood-related toxicity.
The study utilized 48 male Wistar rats split into six groups, with treatment cohorts receiving 10 mg/kg of nicotine and varying aprepitant doses of 20, 40, or 80 mg/kg. Researchers observed improvements in histopathological outcomes within the hippocampus DG and CA1 regions after three weeks of daily treatment.
The players
Wistar rats
These laboratory rats are a common outbred strain used extensively in biomedical research for testing pharmaceutical effects.
The details
Administered via daily intraperitoneal injections, aprepitant reversed behavioral disturbances and normalized levels of oxidative stress markers like ROS, MDA, and H2O2. The treatment also increased essential energy-producing markers and cell-survival proteins such as unphosphorylated Bcl-2 compared to control groups.
Timeline
The treatment period for the study groups lasted for three weeks.
The Big Picture
This study contributes to the ongoing research into neuroinflammation in the hippocampus by identifying a potential pharmaceutical agent to mitigate cellular damage. It marks a shift toward investigating specific drug candidates that may protect against chemical-induced brain toxicity.
While promising in animal models, this research does not currently offer a treatment or behavioral change for human patients. Readers should continue to monitor medical news for future clinical trials that would determine if these findings have implications for human therapy.
The takeaway
This research underscores the complex relationship between nicotine exposure and hippocampal neurotoxicity. Future studies are required to establish whether aprepitant or similar compounds can safely provide neuroprotective benefits for individuals dealing with cognitive impacts.
Further reading
For more information on the evolving landscape of brain health research, see our Alzheimer’s section.
More information
Read the complete scientific study publication for detailed methodology and results.
Source note: This article includes information reported by Nature.
